首页 > 最新文献

Cardiology Research最新文献

英文 中文
Does Sinus Rhythm Restoration in Patients With Atrial Fibrillation Undergoing Pulmonary Vein Isolation Have Acute Hemodynamic Benefits? 接受肺静脉隔离治疗的心房颤动患者恢复窦性心律是否对急性血流动力学有益?
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-01 Epub Date: 2024-08-20 DOI: 10.14740/cr1692
Tomo Komaki, Noriyuki Mohri, Akihito Ideishi, Kohei Tashiro, Naoko Koyanagi, Shin-Ichiro Miura, Masahiro Ogawa

Background: Although the restoration and maintenance of sinus rhythm (SR) in patients with atrial fibrillation (AF) have long-term benefits, few studies have investigated the acute hemodynamic benefits immediately after SR restoration. Therefore, we investigated whether hemodynamic changes occurred in the first few minutes after cardioversion from AF to SR.

Methods: We retrospectively enrolled 145 patients with AF and divided them into a pre-AF group comprising patients in whom SR was restored by electrical cardioversion during pulmonary vein isolation (PVI; n = 74) and a control group comprising patients who were in SR throughout the procedure (n = 71). The pre-AF group was subdivided into subgroups according to AF classification (paroxysmal AF (PAF), persistent AF (PerAF), and long-standing persistent AF (LSPAF)) and into quartiles based on the AF-heart rate (HR). The mean arterial pressure (MAP) and left atrial pressure (LAP) were measured immediately after transseptal puncture (pre-measurement) and before withdrawal from the left atrium after PVI (post-measurement). The changes in MAP and LAP between the pre- and post-measurement (ΔMAP and ΔLAP) were calculated by subtracting the pre-measurements (MAPpre and LAPpre) from the post-measurements (MAPpost and LAPpost).

Results: In the pre-AF group, the time from cardioversion to post-measurement was 19 ± 16 min. When ΔMAP and ΔLAP were compared with the control group, ΔMAP was significantly smaller (4.9 ± 17.8 vs. 11.0 ± 14.2 mm Hg, respectively; P = 0.025), and ΔLAP was not significantly different between the groups. In the subgroup analyses, although ΔLAP was not significantly different among AF types, ΔMAP was significantly increased in the PAF group compared to the PerAF and LSPAF groups (24.0 ± 18.5 vs. 3.1 ± 16.8 and 4.5 ± 18.1 mm Hg, respectively; P = 0.042). The HRpre in the quartiles with the lowest, second, third, and highest AF-HR were approximately 58, 74, 86, and 109 beats per minute (bpm), respectively. The ΔLAP and ΔMAP were not significantly different among the AF-HR quartile groups.

Conclusions: In patients with PAF, atrial contractions may resume quickly, which leads to hemodynamic improvement immediately after SR restoration. As for AF-HR, there was no significant impairment of ventricular diastolic filling at approximately < 109 bpm.

背景:尽管恢复和维持心房颤动(房颤)患者的窦性心律(SR)具有长期的益处,但很少有研究调查了SR恢复后立即出现的急性血流动力学益处。因此,我们研究了从房颤转为窦性心律后最初几分钟内血液动力学是否发生了变化:我们回顾性地纳入了 145 名房颤患者,并将其分为房颤前组和对照组,前者包括在肺静脉隔离术(PVI)中通过心脏电复律恢复 SR 的患者(n = 74),后者包括在整个手术过程中均处于 SR 状态的患者(n = 71)。根据房颤分类(阵发性房颤(PAF)、持续性房颤(PerAF)和长期持续性房颤(LSPAF))和房颤-心率(HR)的四分法,将房颤前组细分为不同的亚组。经脐穿刺后立即测量平均动脉压(MAP)和左心房压(LAP)(测量前),PVI 后退出左心房前测量平均动脉压(MAP)和左心房压(LAP)(测量后)。将测量前的数据(MAPpre 和 LAPpre)减去测量后的数据(MAPpost 和 LAPpost),计算出测量前后 MAP 和 LAP 的变化(ΔMAP 和 ΔLAP):结果:在预AF组中,从心脏复律到测量后的时间为19 ± 16分钟。ΔMAP和ΔLAP与对照组相比,ΔMAP明显较小(分别为4.9 ± 17.8 vs. 11.0 ± 14.2 mm Hg;P = 0.025),而ΔLAP在组间无明显差异。在亚组分析中,虽然ΔLAP 在不同房颤类型之间无明显差异,但与 PerAF 组和 LSPAF 组相比,PAF 组的ΔMAP 明显增加(分别为 24.0 ± 18.5 vs. 3.1 ± 16.8 和 4.5 ± 18.1 mm Hg;P = 0.042)。最低、第二、第三和最高 AF-HR 四分位数的 HRpre 分别约为 58、74、86 和 109 次/分(bpm)。ΔLAP和ΔMAP在心房颤动-房颤四分位数组之间无明显差异:结论:在 PAF 患者中,心房收缩可能很快恢复,这导致 SR 恢复后血流动力学立即改善。至于 AF-HR,在约 < 109 bpm 时,心室舒张充盈没有明显受损。
{"title":"Does Sinus Rhythm Restoration in Patients With Atrial Fibrillation Undergoing Pulmonary Vein Isolation Have Acute Hemodynamic Benefits?","authors":"Tomo Komaki, Noriyuki Mohri, Akihito Ideishi, Kohei Tashiro, Naoko Koyanagi, Shin-Ichiro Miura, Masahiro Ogawa","doi":"10.14740/cr1692","DOIUrl":"10.14740/cr1692","url":null,"abstract":"<p><strong>Background: </strong>Although the restoration and maintenance of sinus rhythm (SR) in patients with atrial fibrillation (AF) have long-term benefits, few studies have investigated the acute hemodynamic benefits immediately after SR restoration. Therefore, we investigated whether hemodynamic changes occurred in the first few minutes after cardioversion from AF to SR.</p><p><strong>Methods: </strong>We retrospectively enrolled 145 patients with AF and divided them into a pre-AF group comprising patients in whom SR was restored by electrical cardioversion during pulmonary vein isolation (PVI; n = 74) and a control group comprising patients who were in SR throughout the procedure (n = 71). The pre-AF group was subdivided into subgroups according to AF classification (paroxysmal AF (PAF), persistent AF (PerAF), and long-standing persistent AF (LSPAF)) and into quartiles based on the AF-heart rate (HR). The mean arterial pressure (MAP) and left atrial pressure (LAP) were measured immediately after transseptal puncture (pre-measurement) and before withdrawal from the left atrium after PVI (post-measurement). The changes in MAP and LAP between the pre- and post-measurement (ΔMAP and ΔLAP) were calculated by subtracting the pre-measurements (MAP<sub>pre</sub> and LAP<sub>pre</sub>) from the post-measurements (MAP<sub>post</sub> and LAP<sub>post</sub>).</p><p><strong>Results: </strong>In the pre-AF group, the time from cardioversion to post-measurement was 19 ± 16 min. When ΔMAP and ΔLAP were compared with the control group, ΔMAP was significantly smaller (4.9 ± 17.8 vs. 11.0 ± 14.2 mm Hg, respectively; P = 0.025), and ΔLAP was not significantly different between the groups. In the subgroup analyses, although ΔLAP was not significantly different among AF types, ΔMAP was significantly increased in the PAF group compared to the PerAF and LSPAF groups (24.0 ± 18.5 vs. 3.1 ± 16.8 and 4.5 ± 18.1 mm Hg, respectively; P = 0.042). The HR<sub>pre</sub> in the quartiles with the lowest, second, third, and highest AF-HR were approximately 58, 74, 86, and 109 beats per minute (bpm), respectively. The ΔLAP and ΔMAP were not significantly different among the AF-HR quartile groups.</p><p><strong>Conclusions: </strong>In patients with PAF, atrial contractions may resume quickly, which leads to hemodynamic improvement immediately after SR restoration. As for AF-HR, there was no significant impairment of ventricular diastolic filling at approximately < 109 bpm.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"15 4","pages":"298-308"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11349134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Notice to "Sacubitril/Valsartan Therapy for 14 Months Induces a Marked Improvement of Global Longitudinal Strain in Patients With Chronic Heart Failure: A Retrospective Cohort Study". 萨库比特利/缬沙坦治疗 14 个月可明显改善慢性心力衰竭患者的整体纵向应变》的撤稿通知:一项回顾性队列研究"。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-01 Epub Date: 2024-08-20 DOI: 10.14740/cr910r

[This retracts the article DOI: 10.14740/cr910.].

[这篇文章撤消了 DOI: 10.14740/cr910.]。
{"title":"Retraction Notice to \"Sacubitril/Valsartan Therapy for 14 Months Induces a Marked Improvement of Global Longitudinal Strain in Patients With Chronic Heart Failure: A Retrospective Cohort Study\".","authors":"","doi":"10.14740/cr910r","DOIUrl":"10.14740/cr910r","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.14740/cr910.].</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"15 4","pages":"318"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11349136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Usefulness of Serum Testosterone Concentration and Skin Autofluorescence as Coronary Risk Markers in Male Patients With Type 2 Diabetes Mellitus. 血清睾酮浓度和皮肤自发荧光作为 2 型糖尿病男性患者冠心病风险标志物的实用性。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-01 Epub Date: 2024-07-30 DOI: 10.14740/cr1686
Takashi Hitsumoto

Background: No studies have reported simultaneous evaluation of the two coronary risk markers of testosterone and skin autofluorescence (SAF) as a marker of advanced glycation end products in patients with type 2 diabetes mellitus (T2DM) at present. This study aimed to clarify the clinical significance of both indicators as risk markers of coronary artery disease (CAD), including the association and background factors between testosterone and SAF in male patients with T2DM.

Methods: This study enrolled 162 male patients with T2DM (CAD: n = 35). Testosterone was evaluated by serum total testosterone concentration (T-T). Various analyses related to T-T and SAF as coronary risk markers were performed.

Results: T-T was significantly lower, and SAF was significantly higher in patients with CAD than in patients with non-CAD. A significant negative correlation was found between T-T and SAF (r = -0.45, P < 0.001), and the correlation was stronger in patients with CAD than in patients with non-CAD (non-CAD, r = -0.27, P = 0.003; CAD, r = -0.51, P < 0.001). However, both T-T and SAF had significant associations with triglyceride-glucose index as an insulin resistance marker and cardio-ankle vascular index as an arterial function marker. Multiple regression analysis revealed that both T-T and SAF were selected as independent variables to the presence of CAD as a dependent variable. However, the odds ratio increased due to the merger of two coronary risk markers, low T-T and high SAF (odds ratio: one risk marker: 3.24, 95% confidence interval: 1.01 - 10.50, P = 0.045; two risk markers: 13.22, 95% confidence interval: 3.41 - 39.92, P < 0.001).

Conclusions: The results of this cross-sectional study indicate that T-T and SAF are closely related in CAD patients with T2DM. It also shows that insulin resistance and arterial dysfunction are in the background of both indicators. Additionally, not only are both indicators independent coronary risk markers, but the overlap of both indicators increases their weight as coronary risk markers.

研究背景目前还没有研究报道同时评估睾酮和皮肤自发荧光(SAF)这两个冠状动脉风险标志物作为2型糖尿病(T2DM)患者晚期糖化终末产物的标志物。本研究旨在阐明这两项指标作为冠状动脉疾病(CAD)风险标志物的临床意义,包括睾酮和皮肤自发荧光(SAF)在男性T2DM患者中的关联和背景因素:本研究招募了 162 名男性 T2DM 患者(CAD:35 人)。睾酮通过血清总睾酮浓度(T-T)进行评估。对作为冠状动脉风险标志物的T-T和SAF进行了各种分析:结果:与非冠状动脉粥样硬化患者相比,冠状动脉粥样硬化患者的 T-T 明显较低,而 SAF 则明显较高。T-T和SAF之间存在明显的负相关(r = -0.45,P < 0.001),且CAD患者的相关性强于非CAD患者(非CAD,r = -0.27,P = 0.003;CAD,r = -0.51,P < 0.001)。然而,T-T 和 SAF 与作为胰岛素抵抗标志物的甘油三酯-葡萄糖指数和作为动脉功能标志物的心踝关节血管指数都有显著的相关性。多元回归分析表明,T-T 和 SAF 被选为自变量,而 CAD 的存在则是因变量。然而,由于合并了低 T-T 和高 SAF 这两个冠状动脉风险标志物,几率比增加了(几率比:一个风险标志物:3.24,95% 置信区间:3.24,95% 置信区间:3.24,95% 置信区间:3.24):3.24,95% 置信区间:1.01 - 10.50,P = 0.045;两个风险指标:13.22,95% 置信区间:1.01 - 10.50,P = 0.045:13.22,95% 置信区间结论:这项横断面研究结果表明,T-T 和 SAF 在患有 T2DM 的 CAD 患者中密切相关。结论:这项横断面研究结果表明,T-T 和 SAF 与 T2DM 患者的 CAD 密切相关,同时还表明,胰岛素抵抗和动脉功能障碍是这两项指标的背景。此外,这两个指标不仅是独立的冠心病风险标志物,而且两个指标的重叠增加了它们作为冠心病风险标志物的权重。
{"title":"Usefulness of Serum Testosterone Concentration and Skin Autofluorescence as Coronary Risk Markers in Male Patients With Type 2 Diabetes Mellitus.","authors":"Takashi Hitsumoto","doi":"10.14740/cr1686","DOIUrl":"10.14740/cr1686","url":null,"abstract":"<p><strong>Background: </strong>No studies have reported simultaneous evaluation of the two coronary risk markers of testosterone and skin autofluorescence (SAF) as a marker of advanced glycation end products in patients with type 2 diabetes mellitus (T2DM) at present. This study aimed to clarify the clinical significance of both indicators as risk markers of coronary artery disease (CAD), including the association and background factors between testosterone and SAF in male patients with T2DM.</p><p><strong>Methods: </strong>This study enrolled 162 male patients with T2DM (CAD: n = 35). Testosterone was evaluated by serum total testosterone concentration (T-T). Various analyses related to T-T and SAF as coronary risk markers were performed.</p><p><strong>Results: </strong>T-T was significantly lower, and SAF was significantly higher in patients with CAD than in patients with non-CAD. A significant negative correlation was found between T-T and SAF (r = -0.45, P < 0.001), and the correlation was stronger in patients with CAD than in patients with non-CAD (non-CAD, r = -0.27, P = 0.003; CAD, r = -0.51, P < 0.001). However, both T-T and SAF had significant associations with triglyceride-glucose index as an insulin resistance marker and cardio-ankle vascular index as an arterial function marker. Multiple regression analysis revealed that both T-T and SAF were selected as independent variables to the presence of CAD as a dependent variable. However, the odds ratio increased due to the merger of two coronary risk markers, low T-T and high SAF (odds ratio: one risk marker: 3.24, 95% confidence interval: 1.01 - 10.50, P = 0.045; two risk markers: 13.22, 95% confidence interval: 3.41 - 39.92, P < 0.001).</p><p><strong>Conclusions: </strong>The results of this cross-sectional study indicate that T-T and SAF are closely related in CAD patients with T2DM. It also shows that insulin resistance and arterial dysfunction are in the background of both indicators. Additionally, not only are both indicators independent coronary risk markers, but the overlap of both indicators increases their weight as coronary risk markers.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"15 4","pages":"253-261"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11349139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FASLG as a Key Member of Necroptosis Participats in Acute Myocardial Infarction by Regulating Immune Infiltration. FASLG 是通过调节免疫渗透参与急性心肌梗塞坏死过程的关键成员。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-01 Epub Date: 2024-07-30 DOI: 10.14740/cr1652
Hui Min Jia, Fu Xiang An, Yu Zhang, Mei Zhu Yan, Yi Zhou, Hong Jun Bian

Background: Acute myocardial infarction (AMI) is a major cause of human health risk. Necroptosis is a newly and recently reported mode of cell death, whose role in AMI has not been fully elucidated. This study aimed to search for necroptosis biomarkers associated with the occurrence of AMI and to explore their possible molecular mechanisms through bioinformatics analysis.

Methods: The dataset GSE48060 was used to perform weighted gene co-expression network analysis (WGCNA) and differential analysis. Key modules, differential genes, and necroptosis-related genes (NRGs) were intersected to obtain candidate biomarkers. Groups were classified and differentially analyzed according to the expression of the key biomarker. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, gene set enrichment analysis (GSEA), and construction of protein-protein interaction (PPI) networks are performed on differentially expressed genes (DEGs). Finally, CIBERSORT was used to assess immune cell infiltration in AMI and the correlation of key biomarkers with immune cells. Immune cell infiltration analysis revealed the correlation between FASLG and multiple screened immune cells.

Results: WGCNA determined that the MEsaddlebrown module was the most significantly associated with AMI. Intersecting it with DEGs as well as NRGs, we obtained two key genes, FASLG and IFNG. But only FASLG showed statistically significant differences between the AMI group and the normal control group. Further analysis suggested that the down-regulation of FASLG may exert its function through the regulation of the central genes CD247 and YES1. Furthermore, FASLG was positively correlated with T-cell CD4 memory activation and T-cell gamma delta, and negatively correlated with macrophage M0.

Conclusion: In conclusion, FASLG and its regulatory genes CD247 and YES1 might be involved in the development of AMI by regulating immune cell infiltration. FASLG might be a potential biomarker for AMI and provides a new direction for the diagnosis of AMI.

背景:急性心肌梗死(AMI急性心肌梗死(AMI)是危害人类健康的一个主要原因。坏死是一种新近报道的细胞死亡模式,其在急性心肌梗死中的作用尚未完全阐明。本研究旨在寻找与 AMI 发生相关的坏死生物标志物,并通过生物信息学分析探讨其可能的分子机制:方法:利用数据集 GSE48060 进行加权基因共表达网络分析(WGCNA)和差异分析。对关键模块、差异基因和坏死相关基因(NRGs)进行交叉分析,以获得候选生物标记物。根据关键生物标志物的表达情况对组别进行分类和差异分析。对差异表达基因(DEGs)进行基因本体(GO)、京都基因和基因组百科全书(KEGG)富集分析、基因组富集分析(GSEA)和蛋白质-蛋白质相互作用(PPI)网络构建。最后,CIBERSORT 被用来评估 AMI 中的免疫细胞浸润以及关键生物标志物与免疫细胞的相关性。免疫细胞浸润分析显示了 FASLG 与多种筛选出的免疫细胞之间的相关性:WGCNA确定MEsaddlebrown模块与AMI的相关性最大。将其与 DEGs 和 NRGs 相交,我们得到了两个关键基因:FASLG 和 IFNG。但只有 FASLG 在 AMI 组和正常对照组之间有显著的统计学差异。进一步分析表明,FASLG 的下调可能通过调控中心基因 CD247 和 YES1 发挥作用。此外,FASLG与T细胞CD4记忆激活和T细胞γδ呈正相关,与巨噬细胞M0呈负相关:总之,FASLG及其调控基因CD247和YES1可能通过调节免疫细胞浸润参与了AMI的发病。FASLG可能是AMI的潜在生物标志物,为AMI的诊断提供了新的方向。
{"title":"FASLG as a Key Member of Necroptosis Participats in Acute Myocardial Infarction by Regulating Immune Infiltration.","authors":"Hui Min Jia, Fu Xiang An, Yu Zhang, Mei Zhu Yan, Yi Zhou, Hong Jun Bian","doi":"10.14740/cr1652","DOIUrl":"10.14740/cr1652","url":null,"abstract":"<p><strong>Background: </strong>Acute myocardial infarction (AMI) is a major cause of human health risk. Necroptosis is a newly and recently reported mode of cell death, whose role in AMI has not been fully elucidated. This study aimed to search for necroptosis biomarkers associated with the occurrence of AMI and to explore their possible molecular mechanisms through bioinformatics analysis.</p><p><strong>Methods: </strong>The dataset GSE48060 was used to perform weighted gene co-expression network analysis (WGCNA) and differential analysis. Key modules, differential genes, and necroptosis-related genes (NRGs) were intersected to obtain candidate biomarkers. Groups were classified and differentially analyzed according to the expression of the key biomarker. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, gene set enrichment analysis (GSEA), and construction of protein-protein interaction (PPI) networks are performed on differentially expressed genes (DEGs). Finally, CIBERSORT was used to assess immune cell infiltration in AMI and the correlation of key biomarkers with immune cells. Immune cell infiltration analysis revealed the correlation between FASLG and multiple screened immune cells.</p><p><strong>Results: </strong>WGCNA determined that the MEsaddlebrown module was the most significantly associated with AMI. Intersecting it with DEGs as well as NRGs, we obtained two key genes, FASLG and IFNG. But only FASLG showed statistically significant differences between the AMI group and the normal control group. Further analysis suggested that the down-regulation of FASLG may exert its function through the regulation of the central genes CD247 and YES1. Furthermore, FASLG was positively correlated with T-cell CD4 memory activation and T-cell gamma delta, and negatively correlated with macrophage M0.</p><p><strong>Conclusion: </strong>In conclusion, FASLG and its regulatory genes CD247 and YES1 might be involved in the development of AMI by regulating immune cell infiltration. FASLG might be a potential biomarker for AMI and provides a new direction for the diagnosis of AMI.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"15 4","pages":"262-274"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11349138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remote Ischemic Conditioning Improves Cardiovascular Function in Heart Failure Patients. 远程缺血调节改善心衰患者的心血管功能
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-01 Epub Date: 2024-07-18 DOI: 10.14740/cr1669
Miin-Yaw Shyu, Andrew Ying-Siu Lee

Background: Recently, it has been shown that remote ischemic conditioning (RIC) can be used as a healthy regimen to reverse disease and aging. With this in mind, we are studying the consequences of RIC on cardiovascular function in heart failure patients.

Methods: Forty patients with stable heart failure were prospectively enlisted and randomly divided into RIC (n = 20) and control (n = 20) groups. The RIC protocol consists of a 3-min inflation and then deflation of the blood pressure cuff attached to the upper arm to produce transient ischemia of the arm. RIC treatment was performed once daily for 1 year. NYHA class, left ventricular ejection fraction (LVEF), left atrial and ventricular dimensions were all assessed in two groups.

Results: RIC was well tolerated. After 1 year of treatment, New York Heart Association (NYHA) class improved and LVEF showed a significant increase from 37.11% to 52.44% (P < 0.0001). Additionally, the dimensions of the left atrium (from 50.55 to 43.25 mm) and ventricle (from 53.04 to 50.15 mm) were significantly reduced in the RIC group.

Conclusion: This study suggests that 1 year of RIC treatment as a health strategy could improve cardiovascular function in heart failure patients, leading to its widespread use in these patients.

背景:最近有研究表明,远程缺血调理(RIC)可作为一种健康疗法来逆转疾病和衰老。有鉴于此,我们正在研究 RIC 对心衰患者心血管功能的影响:方法:我们对 40 名稳定型心衰患者进行了前瞻性招募,并将其随机分为 RIC 组(20 人)和对照组(20 人)。RIC 方案包括将连接在上臂的血压袖带充气 3 分钟,然后放气,以产生短暂的手臂缺血。RIC 治疗每天进行一次,持续 1 年。对两组患者的 NYHA 分级、左心室射血分数(LVEF)、左心房和左心室尺寸进行评估:结果:RIC 的耐受性良好。治疗一年后,纽约心脏协会(NYHA)分级得到改善,左心室射血分数(LVEF)从 37.11% 显著增加到 52.44%(P < 0.0001)。此外,RIC 组的左心房(从 50.55 毫米降至 43.25 毫米)和左心室(从 53.04 毫米降至 50.15 毫米)的尺寸也明显缩小:本研究表明,作为一种健康策略,RIC 治疗 1 年可改善心衰患者的心血管功能,因此可在这些患者中广泛使用。
{"title":"Remote Ischemic Conditioning Improves Cardiovascular Function in Heart Failure Patients.","authors":"Miin-Yaw Shyu, Andrew Ying-Siu Lee","doi":"10.14740/cr1669","DOIUrl":"10.14740/cr1669","url":null,"abstract":"<p><strong>Background: </strong>Recently, it has been shown that remote ischemic conditioning (RIC) can be used as a healthy regimen to reverse disease and aging. With this in mind, we are studying the consequences of RIC on cardiovascular function in heart failure patients.</p><p><strong>Methods: </strong>Forty patients with stable heart failure were prospectively enlisted and randomly divided into RIC (n = 20) and control (n = 20) groups. The RIC protocol consists of a 3-min inflation and then deflation of the blood pressure cuff attached to the upper arm to produce transient ischemia of the arm. RIC treatment was performed once daily for 1 year. NYHA class, left ventricular ejection fraction (LVEF), left atrial and ventricular dimensions were all assessed in two groups.</p><p><strong>Results: </strong>RIC was well tolerated. After 1 year of treatment, New York Heart Association (NYHA) class improved and LVEF showed a significant increase from 37.11% to 52.44% (P < 0.0001). Additionally, the dimensions of the left atrium (from 50.55 to 43.25 mm) and ventricle (from 53.04 to 50.15 mm) were significantly reduced in the RIC group.</p><p><strong>Conclusion: </strong>This study suggests that 1 year of RIC treatment as a health strategy could improve cardiovascular function in heart failure patients, leading to its widespread use in these patients.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"15 4","pages":"309-313"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11349135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Major Adverse Cardiovascular Events and Left Ventricular Mass Index in Patients Who Have Undergone Coronary Computed Tomography Angiography: From the FU-CCTA Registry. 接受冠状动脉计算机断层扫描血管造影术患者的主要不良心血管事件与左心室质量指数之间的关系:来自 FU-CCTA 注册。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-01 Epub Date: 2024-06-25 DOI: 10.14740/cr1655
Tetsuro Tachibana, Yuhei Shiga, Kohei Tashiro, Sara Higashi, Yuka Shibata, Yuto Kawahira, Yuta Kato, Takashi Kuwano, Makoto Sugihara, Shin-Ichiro Miura

Background: Left ventricular mass (LVM) is a predictor of future cardiovascular risk. We determined the association between LVM measured by coronary computed tomography angiography (CCTA) and the prognosis in patients who have undergone CCTA for screening of coronary artery disease (CAD).

Methods: We performed a prospective cohort study. Five hundred twenty consecutive patients who underwent CCTA at Fukuoka University Hospital (FU-CCTA registry) were enrolled. They were clinically suspected of having CAD or had at least one cardiovascular risk factor, and were a follow-up of up to 5 years. Equal to more than 50% of coronary stenosis as assessed by CCTA was diagnosed as CAD. Using CCTA, LVM index (LVMI), LV ejection fraction (LVEF), LV end-diastolic volume (LVEDV) and LV end-systolic volume were measured. The primary endpoint was major adverse cardiovascular events (MACEs: including all causes of death, ischemic stroke, acute myocardial infarction and coronary revascularization). The patients were divided into non-MACEs and MACEs groups.

Results: The non-MACEs and MACEs groups consisted of 478 and 42 patients, respectively. Percent of CAD in the MACEs group was significantly higher than that in the non-MACEs group. The MACEs group showed significantly higher LVMI and tended to have a lower LVEF and LVEDV than the non-MACEs group. Although LVMI was not associated with MACEs in all patients, LVMI was independently associated with MACEs in males (odd ratio: 1.018, 95% confidence interval: 1.002 - 1.035, P = 0.030), but not females.

Conclusions: Evaluation of LVMI by CCTA may be useful for predicting MACEs in males.

背景:左心室质量(LVM)是预测未来心血管风险的一个指标。我们测定了通过冠状动脉计算机断层扫描血管造影术(CCTA)测量的左心室质量与接受 CCTA 检查以筛查冠状动脉疾病(CAD)的患者的预后之间的关系:我们进行了一项前瞻性队列研究。方法:我们进行了一项前瞻性队列研究,共纳入了 520 名在福冈大学医院接受过 CCTA 的连续患者(FU-CCTA 登记)。他们在临床上被怀疑患有 CAD 或至少有一个心血管危险因素,并接受了长达 5 年的随访。经 CCTA 评估,冠状动脉狭窄程度等于或超过 50%,即可诊断为 CAD。使用 CCTA 测量左心室容积指数(LVMI)、左心室射血分数(LVEF)、左心室舒张末期容积(LVEDV)和左心室收缩末期容积。主要终点是主要不良心血管事件(MACEs:包括所有死亡原因、缺血性中风、急性心肌梗死和冠状动脉血运重建)。患者被分为非MACEs组和MACEs组:非MACEs组和MACEs组分别有478名和42名患者。MACEs组的CAD百分比明显高于非MACEs组。MACEs 组的 LVMI 明显高于非 MACEs 组,LVEF 和 LVEDV 也往往低于非 MACEs 组。虽然所有患者的 LVMI 均与 MACE 无关,但男性患者的 LVMI 与 MACE 独立相关(奇数比:1.018,95% 置信区间:1.002 - 1.035,P = 0.030),而女性患者的 LVMI 与 MACE 无关:结论:通过 CCTA 评估 LVMI 可能有助于预测男性的 MACE。
{"title":"Association Between Major Adverse Cardiovascular Events and Left Ventricular Mass Index in Patients Who Have Undergone Coronary Computed Tomography Angiography: From the FU-CCTA Registry.","authors":"Tetsuro Tachibana, Yuhei Shiga, Kohei Tashiro, Sara Higashi, Yuka Shibata, Yuto Kawahira, Yuta Kato, Takashi Kuwano, Makoto Sugihara, Shin-Ichiro Miura","doi":"10.14740/cr1655","DOIUrl":"10.14740/cr1655","url":null,"abstract":"<p><strong>Background: </strong>Left ventricular mass (LVM) is a predictor of future cardiovascular risk. We determined the association between LVM measured by coronary computed tomography angiography (CCTA) and the prognosis in patients who have undergone CCTA for screening of coronary artery disease (CAD).</p><p><strong>Methods: </strong>We performed a prospective cohort study. Five hundred twenty consecutive patients who underwent CCTA at Fukuoka University Hospital (FU-CCTA registry) were enrolled. They were clinically suspected of having CAD or had at least one cardiovascular risk factor, and were a follow-up of up to 5 years. Equal to more than 50% of coronary stenosis as assessed by CCTA was diagnosed as CAD. Using CCTA, LVM index (LVMI), LV ejection fraction (LVEF), LV end-diastolic volume (LVEDV) and LV end-systolic volume were measured. The primary endpoint was major adverse cardiovascular events (MACEs: including all causes of death, ischemic stroke, acute myocardial infarction and coronary revascularization). The patients were divided into non-MACEs and MACEs groups.</p><p><strong>Results: </strong>The non-MACEs and MACEs groups consisted of 478 and 42 patients, respectively. Percent of CAD in the MACEs group was significantly higher than that in the non-MACEs group. The MACEs group showed significantly higher LVMI and tended to have a lower LVEF and LVEDV than the non-MACEs group. Although LVMI was not associated with MACEs in all patients, LVMI was independently associated with MACEs in males (odd ratio: 1.018, 95% confidence interval: 1.002 - 1.035, P = 0.030), but not females.</p><p><strong>Conclusions: </strong>Evaluation of LVMI by CCTA may be useful for predicting MACEs in males.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"15 3","pages":"134-143"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Aspirin Use on the Adverse Outcomes in Patients Hospitalized for COVID-19. 使用阿司匹林对 COVID-19 住院患者不良后果的影响
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-01 Epub Date: 2024-06-25 DOI: 10.14740/cr1645
Poornima Vinod, Vinod Krishnappa, William Rathell, Saira Amir, Subrina Sundil, Godwin Dogbey, Hiten Patel, William Herzog

Background: Coronavirus disease 2019 (COVID-19) triggers multiple components of the immune system and causes inflammation of endothelial walls across vascular beds, resulting in respiratory failure, arterial and venous thrombosis, myocardial injury, and multi-organ failure leading to death. Early in the COVID-19 pandemic, aspirin was suggested for the treatment of symptomatic individuals, given its analgesic, antipyretic, anti-inflammatory, anti-thrombotic, and antiviral effects. This study aimed to evaluate the association of aspirin use with various clinical outcomes in patients hospitalized for COVID-19.

Methods: This was a retrospective study involving patients aged ≥ 18 years and hospitalized for COVID-19 from March 2020 to October 2020. Primary outcomes were acute cardiovascular events (ST elevation myocardial infarction (STEMI), type 1 non-ST elevation myocardial infarction (NSTEMI), acute congestive heart failure (CHF), and acute stroke) and death. Secondary outcomes were respiratory failure, need for mechanical ventilation, and acute deep vein thrombosis (DVT)/pulmonary embolism (PE).

Results: Of 376 patients hospitalized for COVID-19, 128 were taking aspirin. Significant proportions of native Americans were hospitalized for COVID-19 in both aspirin (22.7%) and non-aspirin (24.6%) groups. Between aspirin and non-aspirin groups, no significant differences were found with regard to mechanical ventilator support (21.1% vs. 15.3%, P = 0.16), acute cardiovascular events (7.8% vs. 5.2%, P = 0.32), acute DVT/PE (3.9% vs. 5.2%, P = 0.9), readmission rate (13.3% vs. 12.9%, P = 0.91) and mortality (23.4% vs. 20.2%, P = 0.5); however, the median duration of mechanical ventilation was significantly shorter (7 vs. 9 days, P = 0.04) and median length of hospitalization was significantly longer (5.5 vs. 4 days, P = 0.01) in aspirin group compared to non-aspirin group.

Conclusion: No significant differences were found in acute cardiovascular events, acute DVT/PE, mechanical ventilator support, and mortality rate between hospitalized COVID-19 patients who were taking aspirin compared to those not taking aspirin. However, larger studies are required to confirm our findings.

背景:2019 年冠状病毒病(COVID-19)会引发免疫系统的多种成分,并导致血管床内皮壁发炎,导致呼吸衰竭、动静脉血栓形成、心肌损伤和多器官衰竭,最终导致死亡。在 COVID-19 大流行的早期,由于阿司匹林具有镇痛、解热、消炎、抗血栓和抗病毒的作用,因此被建议用于治疗有症状的患者。本研究旨在评估因 COVID-19 而住院的患者使用阿司匹林与各种临床结果之间的关系:这是一项回顾性研究,涉及 2020 年 3 月至 2020 年 10 月期间因 COVID-19 住院且年龄≥ 18 岁的患者。主要结果为急性心血管事件(ST段抬高型心肌梗死(STEMI)、1型非ST段抬高型心肌梗死(NSTEMI)、急性充血性心力衰竭(CHF)和急性卒中)和死亡。次要结果为呼吸衰竭、机械通气需求和急性深静脉血栓(DVT)/肺栓塞(PE):在376名因COVID-19住院的患者中,有128人服用阿司匹林。在阿司匹林组(22.7%)和非阿司匹林组(24.6%)中,因 COVID-19 住院的美国本地人比例都很高。阿司匹林组和非阿司匹林组在机械呼吸机支持(21.1% vs. 15.3%,P = 0.16)、急性心血管事件(7.8% vs. 5.2%,P = 0.32)、急性深静脉血栓/PE(3.9% vs. 5.2%,P = 0.9)、再入院率(13.3% vs. 12.9%,P = 0.91)和死亡率(23.4% vs. 20.2%,P = 0.5);然而,与非阿司匹林组相比,阿司匹林组机械通气的中位持续时间显著缩短(7 vs. 9天,P = 0.04),中位住院时间显著延长(5.5 vs. 4天,P = 0.01):结论:与未服用阿司匹林的患者相比,服用阿司匹林的 COVID-19 住院患者在急性心血管事件、急性深静脉血栓/动脉粥样硬化、机械呼吸机支持和死亡率方面无明显差异。不过,还需要更大规模的研究来证实我们的发现。
{"title":"Effect of Aspirin Use on the Adverse Outcomes in Patients Hospitalized for COVID-19.","authors":"Poornima Vinod, Vinod Krishnappa, William Rathell, Saira Amir, Subrina Sundil, Godwin Dogbey, Hiten Patel, William Herzog","doi":"10.14740/cr1645","DOIUrl":"10.14740/cr1645","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) triggers multiple components of the immune system and causes inflammation of endothelial walls across vascular beds, resulting in respiratory failure, arterial and venous thrombosis, myocardial injury, and multi-organ failure leading to death. Early in the COVID-19 pandemic, aspirin was suggested for the treatment of symptomatic individuals, given its analgesic, antipyretic, anti-inflammatory, anti-thrombotic, and antiviral effects. This study aimed to evaluate the association of aspirin use with various clinical outcomes in patients hospitalized for COVID-19.</p><p><strong>Methods: </strong>This was a retrospective study involving patients aged ≥ 18 years and hospitalized for COVID-19 from March 2020 to October 2020. Primary outcomes were acute cardiovascular events (ST elevation myocardial infarction (STEMI), type 1 non-ST elevation myocardial infarction (NSTEMI), acute congestive heart failure (CHF), and acute stroke) and death. Secondary outcomes were respiratory failure, need for mechanical ventilation, and acute deep vein thrombosis (DVT)/pulmonary embolism (PE).</p><p><strong>Results: </strong>Of 376 patients hospitalized for COVID-19, 128 were taking aspirin. Significant proportions of native Americans were hospitalized for COVID-19 in both aspirin (22.7%) and non-aspirin (24.6%) groups. Between aspirin and non-aspirin groups, no significant differences were found with regard to mechanical ventilator support (21.1% vs. 15.3%, P = 0.16), acute cardiovascular events (7.8% vs. 5.2%, P = 0.32), acute DVT/PE (3.9% vs. 5.2%, P = 0.9), readmission rate (13.3% vs. 12.9%, P = 0.91) and mortality (23.4% vs. 20.2%, P = 0.5); however, the median duration of mechanical ventilation was significantly shorter (7 vs. 9 days, P = 0.04) and median length of hospitalization was significantly longer (5.5 vs. 4 days, P = 0.01) in aspirin group compared to non-aspirin group.</p><p><strong>Conclusion: </strong>No significant differences were found in acute cardiovascular events, acute DVT/PE, mechanical ventilator support, and mortality rate between hospitalized COVID-19 patients who were taking aspirin compared to those not taking aspirin. However, larger studies are required to confirm our findings.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"15 3","pages":"179-188"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel Case of Anomalous Origin of Left Vertebral Artery Associated With Left Subclavian Steal Syndrome. 左锁骨下动脉盗血综合征伴左侧椎动脉起源异常的新病例
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-01 Epub Date: 2024-06-25 DOI: 10.14740/cr1672
Poornima Vinod, Hiten Patel

The subclavian steal syndrome (SSS) is defined by the reversal of flow in the ipsilateral vertebral artery in the setting of subclavian artery stenosis proximal to its origin. Here, we describe a rare case of left SSS with significant left subclavian artery stenosis associated with anomalous origin of the left vertebral artery (LVA) directly from the aortic arch in a patient presenting with signs of vertebrobasilar insufficiency and resolution of symptoms following angioplasty. Through this case, the authors try to emphasize the importance and the correct technique of using Doppler ultrasonography, and the importance of invasive angiography in understanding the mechanism of subclavian steal in patients with anomalous LVA origin.

锁骨下盗血综合征(SSS)是指在锁骨下动脉近端狭窄的情况下,同侧椎动脉血流发生逆转。在此,我们描述了一例罕见的左侧 SSS 病例,患者左侧锁骨下动脉明显狭窄,左侧椎动脉(LVA)直接从主动脉弓异常起源,表现为椎基底动脉供血不足,血管成形术后症状缓解。通过这个病例,作者试图强调使用多普勒超声检查的重要性和正确技术,以及有创血管造影术对了解锁骨下盗血机制的重要性。
{"title":"A Novel Case of Anomalous Origin of Left Vertebral Artery Associated With Left Subclavian Steal Syndrome.","authors":"Poornima Vinod, Hiten Patel","doi":"10.14740/cr1672","DOIUrl":"10.14740/cr1672","url":null,"abstract":"<p><p>The subclavian steal syndrome (SSS) is defined by the reversal of flow in the ipsilateral vertebral artery in the setting of subclavian artery stenosis proximal to its origin. Here, we describe a rare case of left SSS with significant left subclavian artery stenosis associated with anomalous origin of the left vertebral artery (LVA) directly from the aortic arch in a patient presenting with signs of vertebrobasilar insufficiency and resolution of symptoms following angioplasty. Through this case, the authors try to emphasize the importance and the correct technique of using Doppler ultrasonography, and the importance of invasive angiography in understanding the mechanism of subclavian steal in patients with anomalous LVA origin.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"15 3","pages":"205-209"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disparity in the Under-Utilization of Novel P2Y12 Inhibitors in ST-Elevation Myocardial Infarction Following Percutaneous Coronary Intervention. 新型 P2Y12 抑制剂在经皮冠状动脉介入治疗 STEV 心肌梗死中使用不足的差异。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-01 Epub Date: 2024-06-25 DOI: 10.14740/cr1528
Chad Nicholson, Maxim Zlatopolsky, Jared Steinberger, Jacob Alex, Marcel Zughaib

Background: The most recent guidelines (European Society of Cardiology (ESC) and American College of Cardiology/American Heart Association (ACC/AHA)) all favor prasugrel/ticagrelor over clopidogrel in the setting of acute coronary syndrome (ACS). We therefore sought to investigate which P2Y12 inhibitors were being prescribed in our community hospital setting upon discharge among patients undergoing percutaneous coronary intervention (PCI) in the setting of ST-elevation myocardial infarction (STEMI).

Methods: We identified patients presenting to two Metro Detroit Michigan hospitals with STEMI between January 1, 2018, to December 31, 2021 using the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) PCI registry. The primary outcome was the choice of P2Y12 inhibitor prescribed on day of discharge following hospitalization for STEMI, and baseline characteristics were compared including race, sex and type of insurance.

Results: A total of 366 patients presented to these two Metro Detroit hospitals from January 1, 2018, to December 31, 2021. Female and non-White patients were more likely to be discharged on clopidogrel than ticagrelor or prasugrel (odds ratio (OR): 1.56, confidence interval (CI): 0.99 - 2.45, and OR: 1.43, CI: 0.91 - 2.25, respectively), however, did not reach statistical significance. Patients without private insurance presenting with STEMI were more likely to be discharged on clopidogrel (OR: 1.83, CI: 1.22 - 2.74), which did reach statistical significance in our cohort.

Conclusions: In this retrospective single-center study evaluating BMC2 registry, we demonstrate a clinically significant disparity in prescribing patterns based on insurance, with trends for disparity based on gender and ethnicity.

背景:最新指南(欧洲心脏病学会 (ESC) 和美国心脏病学会/美国心脏协会 (ACC/AHA))均赞成在急性冠状动脉综合征 (ACS) 情况下使用普拉格雷/替卡格雷,而不是氯吡格雷。因此,我们试图调查在社区医院接受经皮冠状动脉介入治疗(PCI)的ST段抬高型心肌梗死(STEMI)患者出院时处方的P2Y12抑制剂:我们使用密歇根州蓝十字蓝盾心血管联盟(BMC2)PCI 注册表对 2018 年 1 月 1 日至 2021 年 12 月 31 日期间在密歇根州底特律市两家医院就诊的 STEMI 患者进行了鉴定。主要结果是 STEMI 患者住院后出院当天处方 P2Y12 抑制剂的选择,并比较了种族、性别和保险类型等基线特征:从2018年1月1日至2021年12月31日,共有366名患者在这两家底特律大都会医院就诊。与替卡格雷或普拉格雷相比,女性和非白人患者更有可能使用氯吡格雷出院(几率比(OR):1.56,置信区间(CI):0.99 - 2.45;OR:1.43,CI:0.91 - 2.25,分别为1.56和1.43),但未达到统计学意义。没有私人保险的 STEMI 患者出院时更有可能使用氯吡格雷(OR:1.83,CI:1.22 - 2.74),这在我们的队列中具有统计学意义:在这项对 BMC2 登记进行评估的单中心回顾性研究中,我们证明了基于保险的处方模式在临床上存在显著差异,而且基于性别和种族的差异也呈上升趋势。
{"title":"Disparity in the Under-Utilization of Novel P2Y12 Inhibitors in ST-Elevation Myocardial Infarction Following Percutaneous Coronary Intervention.","authors":"Chad Nicholson, Maxim Zlatopolsky, Jared Steinberger, Jacob Alex, Marcel Zughaib","doi":"10.14740/cr1528","DOIUrl":"10.14740/cr1528","url":null,"abstract":"<p><strong>Background: </strong>The most recent guidelines (European Society of Cardiology (ESC) and American College of Cardiology/American Heart Association (ACC/AHA)) all favor prasugrel/ticagrelor over clopidogrel in the setting of acute coronary syndrome (ACS). We therefore sought to investigate which P2Y12 inhibitors were being prescribed in our community hospital setting upon discharge among patients undergoing percutaneous coronary intervention (PCI) in the setting of ST-elevation myocardial infarction (STEMI).</p><p><strong>Methods: </strong>We identified patients presenting to two Metro Detroit Michigan hospitals with STEMI between January 1, 2018, to December 31, 2021 using the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) PCI registry. The primary outcome was the choice of P2Y12 inhibitor prescribed on day of discharge following hospitalization for STEMI, and baseline characteristics were compared including race, sex and type of insurance.</p><p><strong>Results: </strong>A total of 366 patients presented to these two Metro Detroit hospitals from January 1, 2018, to December 31, 2021. Female and non-White patients were more likely to be discharged on clopidogrel than ticagrelor or prasugrel (odds ratio (OR): 1.56, confidence interval (CI): 0.99 - 2.45, and OR: 1.43, CI: 0.91 - 2.25, respectively), however, did not reach statistical significance. Patients without private insurance presenting with STEMI were more likely to be discharged on clopidogrel (OR: 1.83, CI: 1.22 - 2.74), which did reach statistical significance in our cohort.</p><p><strong>Conclusions: </strong>In this retrospective single-center study evaluating BMC2 registry, we demonstrate a clinically significant disparity in prescribing patterns based on insurance, with trends for disparity based on gender and ethnicity.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"15 3","pages":"129-133"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Efficacy of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in the Treatment of Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Recent Randomized Controlled Trials. 经皮冠状动脉介入治疗与冠状动脉旁路移植治疗缺血性心脏病的疗效比较:近期随机对照试验的系统回顾和元分析》。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-01 Epub Date: 2024-06-25 DOI: 10.14740/cr1638
Jordan Llerena-Velastegui, Kristina Zumbana-Podaneva, Sebastian Velastegui-Zurita, Melany Mejia-Mora, Juan Perez-Tomassetti, Allison Cabrera-Cruz, Pablo Haro-Arteaga, Ana Clara Fonseca Souza de Jesus, Pedro Moraes Coelho, Cristian Sanahuja-Montiel

Background: Ischemic heart disease (IHD) is a major global health issue and a leading cause of death. This study compares the effectiveness of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in the management of IHD, focusing on their impact on revascularization, myocardial infarction (MI), and post-procedural stroke. This study aimed to evaluate and compare the effectiveness of PCI and CABG in treating IHD based on an exhaustive literature review of the past 5 years, emphasizing recent advancements and outcomes in IHD management.

Methods: A comprehensive literature review analyzed 32 randomized controlled trials (RCTs) retrieved from databases such as PubMed, Cochrane Library, and Google Scholar. The study specifically assessed the incidences of revascularization, stroke, and MI in patients treated with either PCI or CABG. The comparison between CABG and PCI exclusively focused on lesions with a SYNTAX score exceeding 32.

Results: Our findings highlight CABG's significant efficacy over PCI in reducing revascularization and MI. The aggregated Mantel-Haenszel (M-H) value for revascularization was 1.85 (95% confidence interval (CI): 1.65 - 2.07), signifying CABG's advantage. Additionally, CABG demonstrated superior performance in diminishing MI occurrences (M-H = 2.71, 95% CI: 1.13 - 6.53). In contrast, PCI was more effective in reducing stroke (M-H = 0.80, 95% CI: 0.60 - 1.10).

Conclusion: The study confirms CABG's superiority in reducing revascularization and MI in IHD patients, highlighting PCI's effectiveness in reducing stroke risk. These findings underscore the importance of personalized treatment strategies in IHD management and emphasize the need for ongoing research and evidence-based guidelines to aid in treatment selection for IHD patients.

背景:缺血性心脏病(IHD)是一个重大的全球性健康问题,也是导致死亡的主要原因。本研究比较了经皮冠状动脉介入治疗(PCI)和冠状动脉旁路移植术(CABG)在治疗缺血性心脏病中的有效性,重点关注它们对血管再通、心肌梗死(MI)和术后中风的影响。本研究旨在通过对过去5年的详尽文献进行回顾,评估和比较PCI和CABG治疗IHD的效果,强调IHD治疗的最新进展和结果:综合文献综述分析了从 PubMed、Cochrane Library 和 Google Scholar 等数据库中检索到的 32 项随机对照试验 (RCT)。研究特别评估了接受 PCI 或 CABG 治疗的患者的血管再通、中风和心肌梗死发生率。CABG 和 PCI 的比较只针对 SYNTAX 评分超过 32 分的病变:结果:我们的研究结果表明,在减少血管再通和心肌梗死方面,CABG 比 PCI 有显著疗效。血管再形成的 Mantel-Haenszel (M-H) 总值为 1.85(95% 置信区间 (CI):1.65 - 2.07),显示了 CABG 的优势。此外,CABG 在减少心肌梗死发生率方面也表现出色(M-H = 2.71,95% 置信区间:1.13 - 6.53)。相比之下,PCI 在减少中风方面更为有效(M-H = 0.80,95% CI:0.60 - 1.10):该研究证实了 CABG 在减少 IHD 患者血管再通和心肌梗死方面的优越性,并强调了 PCI 在降低卒中风险方面的有效性。这些研究结果突出了个性化治疗策略在心肌缺血和心脏病治疗中的重要性,并强调了持续研究和循证指南在帮助心肌缺血和心脏病患者选择治疗方法方面的必要性。
{"title":"Comparative Efficacy of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in the Treatment of Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Recent Randomized Controlled Trials.","authors":"Jordan Llerena-Velastegui, Kristina Zumbana-Podaneva, Sebastian Velastegui-Zurita, Melany Mejia-Mora, Juan Perez-Tomassetti, Allison Cabrera-Cruz, Pablo Haro-Arteaga, Ana Clara Fonseca Souza de Jesus, Pedro Moraes Coelho, Cristian Sanahuja-Montiel","doi":"10.14740/cr1638","DOIUrl":"10.14740/cr1638","url":null,"abstract":"<p><strong>Background: </strong>Ischemic heart disease (IHD) is a major global health issue and a leading cause of death. This study compares the effectiveness of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in the management of IHD, focusing on their impact on revascularization, myocardial infarction (MI), and post-procedural stroke. This study aimed to evaluate and compare the effectiveness of PCI and CABG in treating IHD based on an exhaustive literature review of the past 5 years, emphasizing recent advancements and outcomes in IHD management.</p><p><strong>Methods: </strong>A comprehensive literature review analyzed 32 randomized controlled trials (RCTs) retrieved from databases such as PubMed, Cochrane Library, and Google Scholar. The study specifically assessed the incidences of revascularization, stroke, and MI in patients treated with either PCI or CABG. The comparison between CABG and PCI exclusively focused on lesions with a SYNTAX score exceeding 32.</p><p><strong>Results: </strong>Our findings highlight CABG's significant efficacy over PCI in reducing revascularization and MI. The aggregated Mantel-Haenszel (M-H) value for revascularization was 1.85 (95% confidence interval (CI): 1.65 - 2.07), signifying CABG's advantage. Additionally, CABG demonstrated superior performance in diminishing MI occurrences (M-H = 2.71, 95% CI: 1.13 - 6.53). In contrast, PCI was more effective in reducing stroke (M-H = 0.80, 95% CI: 0.60 - 1.10).</p><p><strong>Conclusion: </strong>The study confirms CABG's superiority in reducing revascularization and MI in IHD patients, highlighting PCI's effectiveness in reducing stroke risk. These findings underscore the importance of personalized treatment strategies in IHD management and emphasize the need for ongoing research and evidence-based guidelines to aid in treatment selection for IHD patients.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"15 3","pages":"153-168"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiology Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1